Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update [Yahoo! Finance]
Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update
Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement [Yahoo! Finance]
Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement